94061-80-0

Basic information

• Product Name: SRI 62320
• Synonyms: SRI 62320;(3R,5S)-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic Acid Sodium Salt
• CAS NO: 94061-80-0
• Molecular Formula: C₂₄H₂₅FNO₄*Na
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 94061-80-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: >150°C (dec.)
• Appearance: /
• CAS DataBase Reference: SRI 62320(CAS DataBase Reference)
• NIST Chemistry Reference: SRI 62320(94061-80-0)
• EPA Substance Registry System: SRI 62320(94061-80-0)

Safety Data

• Hazardous Substances Data: 94061-80-0(Hazardous Substances Data)

Usage

Description

SRI 62320 is a synthetic HMG-CoA reductase inhibitor, which is a class of drugs used to lower cholesterol levels in the blood. It is a pale-yellow solid and contains residual sodium chloride, which is quantified on the certificate of analysis.

Uses

Used in Pharmaceutical Industry:
SRI 62320 is used as an antilipemic agent for the treatment of high cholesterol levels. It works by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver, thus reducing the overall cholesterol levels in the blood.

Upstream product

• 194934-96-8 (E)-(3R,5S)-(+)-7-[3-(4-fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid 1,1-dimethylethyl ester 
• 93957-50-7 3-<3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl>-2(E)-propenal 
• 194934-95-7 ((S)-(E))-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-5-hydroxy-3-oxo-6-heptenoic acid 1,1-dimethylethyl ester 
• 786710-21-2 methyl [3R,5S-(E)]-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoate 
• 1254361-97-1 (3R,5S,E)-7-(3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid isopropyl ester 
• 124655-09-0 1,1-dimethylethyl (4R-cis)-6-hydroxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate 
• 154877-92-6 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxane-4-yl)acetic acid 
• 1353637-26-9 [(4R,6S)-6-methanesulfonyloxymethyl-2,2-dimethyl-[1,3]dioxan-4-yl]-acetic acid 
• 1353637-28-1 2-[(4R,6S)-6-methanesulfonyloxymethyl-2,2-dimethyl-[1,3]dioxan-4-yl]-N-methoxy-N-methyl-acetamide 
• 1353637-09-8 2-[(4R,6S)-6-hydroxymethyl-2,2-dimethyl-[1,3]dioxan-4-yl]-N-methoxy-N-methylacetamide 
• 1353637-12-3 2-[(4R,6S)-2,2-dimethyl-6-(1-phenyl-1H-tetrazole-5-sulfonylmethyl)-[1,3]dioxan-4-yl]-N-methoxy-N-methyl-acetamide 
• 1353637-15-6 E-(6-{2-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]vinyl}-[(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl])-N-methoxy-N-methyl-acetamide 
• 1353637-16-7 E-(7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-[(3R,5S)-3,5-dihydroxy-hept-6-enoic acid])-N-methoxy-N-methyl-amide 
• 135054-68-1 (3R,5S)-6-<(methylsulfonyl)oxy>-3,5-O-isopropylidene-3,5-dihydroxyhexanoic acid tert-butyl ester 

Downstream Products

• 93957-54-1 fluvastatin 
• 94061-83-3 Fluvastatin lactone 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF

The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvasatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R2-N-O-R1 moiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof.

Facile and highly enantioselective synthesis of (+)- and (-)-fluvastatin and their analogues

A highly enantioselective synthesis of (+)- and (-)-fluvastatin and their analogues has been facilitated by the reaction of an aldehyde with diketene in the presence of Ti(O-i-Pr)4 and a chiral Schiff base ligand. Either enantiomer of the Schiff base could be employed to obtain (+)- or (-)-fluvastatin. Diastereoselective reductions of the resultant keto moiety of β-hydroxy ketoesters provided the syn-1,3-diol esters (91% ee), which were subsequently recrystallized and saponified to afford (+)- and (-)-fluvastatin in >99.9% ee.

PROCESS FOR PREPARATING ENANTIOMERICALLY PURE FLUVASTATIN SODIUM AND A NOVEL POLYMORPHIC FORM THEREOF

The present invention provides processes for preparing enantiomerically pure fluvastatin sodium. The present invention also provides pharmaceutical compositions comprising the enantiomerically pure fluvastatin sodium for antagonizing HMG-CoA. In addition